Advances in Therapy

, Volume 21, Issue 2, pp 76–86 | Cite as

Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension

  • Maurizio Picca
  • Francesco Agozzino
  • Giancarlo Pelosi


This study compared the effect of losartan and valsartan on left ventricular mass (LVM) and function in patients with untreated essential hypertension and concentric left ventricular hypertrophy (LVH). Thirty patients (17 men and 13 women; mean age, 48±8 years) with untreated essential hypertension and concentric LVH, as determined by echocardiographic assessment, were randomly assigned in equal numbers and double-blind fashion to receive either losartan 50 to 100 mg/d or valsartan 80 to 1 60 mg/d. Doppler echocardiograms were obtained from each patient before treatment, at the time of initial blood pressure control, and then after 6 months. A significant reduction (P<.01) in LVM index was observed in both the losartan group (from 57.1±7.2 g/m2.7 to 51.5±6.1 g/m2.7) and the valsartan group (from 58.1±8.4 g/m2.7 to 48.2±6.2 g/m2.7), but the reduction was higher (P<.05) in the valsartan group. The predicted midwall fractional shortening improved significantly in both the losartan group (from 81±8% to 89±9%, P<.05) and the valsartan group (from 78±7% to 91 ±9%, P<.01). Similarly, the early peak/peak atrial velocity ratio improved significantly both in the losartan group (from 0.78±0.4 to 0.88±0.3, P<.05) and the valsartan group (from 0.84±0.3 to 0.94±0.4, P<.01). These results indicate that valsartan is more effective than losartan in reducing LVM index in hypertensive patients with concentric LVH. This effect is associated with improvement in midwall systolic performance and left ventricular diastolic function.


hypertension cardiac hypertrophy AT receptor antagonists 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.Ann Intern Med. 1991;114: 345–352.PubMedGoogle Scholar
  2. 2.
    de Simone G, Devereux RB, Koren MJ, et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension.Circulation. 1996;93:259–265.PubMedGoogle Scholar
  3. 3.
    Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.Am J Hyperten. 1992;5:95–110.Google Scholar
  4. 4.
    Hernandez R, Sana-Canache B, Velasco M, et al. Angiotensin II receptor antagonists role in arterial hypertension.J Hum Hypertens. 2002;16(suppl 1):S93-S99.CrossRefGoogle Scholar
  5. 5.
    Fyhrquist F, Metsarinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and the pathophysiology of cardiovascular disorders.J Hum Hypertens. 1995;(suppl 5):S19-S24.Google Scholar
  6. 6.
    Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death.Proc Natl Acad Sci USA. 1996;93:156–160.PubMedCrossRefGoogle Scholar
  7. 7.
    Cheung B. Increased left ventricular mass after losartan treatment.Lancet. 1997;349:1743–1744.PubMedCrossRefGoogle Scholar
  8. 8.
    Himmelmann A, Svensson A, Bergbrant A, et al. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension.J Hum Hypertens. 1996;10:729–734.PubMedGoogle Scholar
  9. 9.
    Tedesco MA, Ratti G, Aquino D, et al. Effect of losartan on hypertension and left ventricular mass: a long-term study.J Hum Hypertens. 1998;12:493–495.CrossRefGoogle Scholar
  10. 10.
    Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.Circulation. 1998;98: 2037–2042.PubMedGoogle Scholar
  11. 11.
    Sahn DJ, de Maria A, Kisslo J, et al. Standardization of the American Society of Echocardiography regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation. 1978; 58:1072–1083.PubMedGoogle Scholar
  12. 12.
    Teichholz LE, Krevient T, Herman PV, et al. Problems in echocardiographic volume determinations. Echocardiographic-angiographic correlations in the presence or absence of asinergy.Am J Cardiol. 1976;37:7–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Devereux RB, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.Am J Cardiol. 1986;57:450–458.PubMedCrossRefGoogle Scholar
  14. 14.
    de Simone G, Daniels RS, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and the impact of overweight.J Am Coll Cardiol. 1992;20:1251–1260.PubMedGoogle Scholar
  15. 15.
    Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic wall thickness: identification of severe valvular aortic stenosis in adult patients.Am Heart J. 1982;103:202–203.PubMedCrossRefGoogle Scholar
  16. 16.
    Ganau A, Devereux RB, Casale PN, et al. Patterns of left ventricular and geometric remodeling in essential hypertension.J Am. Coll Cardiol. 1996; 19:259–265.Google Scholar
  17. 17.
    Gaash WH, Zile MR, Hosino PK, et al. Stress-shortening relation and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy.Circulation. 1989; 79:872–883.Google Scholar
  18. 18.
    de Simone G, Devereux RB, Roman MJ, et al. Assessment of left ventricular function by the midwall fractional shortening-end-systolic stress relation in human hypertension.J Am Coll Cardiol. 1994;23:1444–1451.PubMedCrossRefGoogle Scholar
  19. 19.
    DeMaria PN, Wisenbough TW, Smith MD, et al. Doppler echocardiographic evaluation of diastolic dysfunction.Circulation. 1991;84:288–295.Google Scholar
  20. 20.
    Fouad FM, Nakashima Y, Tarazi RC, et al. Reversal of left ventricular hypertrophy with methyldopa.Am J Cardiol. 1982;49:795–801.PubMedCrossRefGoogle Scholar
  21. 21.
    Dunn FG, Ventura HO, Messerli FH, et al. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol.Circulation. 1987;76:254–258.PubMedGoogle Scholar
  22. 22.
    deSimone G, Costantino G, Soro S, et al. Effects of nicardipine on left ventricular hemodynamic patterns in systemic hypertension.Am J Hypertens. 1989;2:139–145.Google Scholar
  23. 23.
    Saragoza MA, Portela JE, Abren P, et al. Regression of left ventricular hypertrophy in the shortterm treatment of hypertension with nicardipine.Am J Hypertens. 1991;4(suppl):1885–1905.Google Scholar
  24. 24.
    Fouad FM, Tarazi RC, Bravo EL. Hemodynamic and cardiac effects of enalapril.Hypertension. 1983;l(suppl 1):135–142.Google Scholar
  25. 25.
    Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril.Am J Cardiol. 1984;53:1044–1049.PubMedCrossRefGoogle Scholar
  26. 26.
    Dahlof B. Effects of angiotensin II blockade on cardiac hypertrophy and remodeling: a review.J Hum Hypertens. 1997;(suppl 2):S9-S17.Google Scholar
  27. 27.
    Liebson PR, Savage DD. Echocardiography: a review. II. Echocardiographic studies on the effects of antihypertensive agents on left ventricular mass and function.Echocardiography. 1987;4:215–249.CrossRefGoogle Scholar
  28. 28.
    Fayerberg B, Beglund A, Andersson OK, et al. Cardiovascular effects of weight reduction versus antihypertensive drug treatment: a comparative, randomized 1-year study of obese men with mild hypertension.J Hyper tens. 1991;9:431–439.CrossRefGoogle Scholar
  29. 29.
    Gradman AH. AT (1) — receptor blockers: differences that matter.J Hum Hypertens. 2002;16(suppl 3): S9-S16.PubMedCrossRefGoogle Scholar
  30. 30.
    Siragy HM, El-Kersh MA, De Gasparo M, et al. Differences in AT2-receptor stimulation between AT1-receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.J Hypertens. 2002;20:1–6.CrossRefGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2004

Authors and Affiliations

  • Maurizio Picca
    • 1
  • Francesco Agozzino
    • 1
  • Giancarlo Pelosi
    • 1
  1. 1.Division of Internal MedicineAzienda Ospedaliera Fatebenefratelli and Oftalmico Macedonio Melloni General HospitalMilanItaly

Personalised recommendations